Pérez-Lamas, Lucía
de Paz Arias, Raquel
Díaz, Rosa Mª Ayala
Montero, Luis Felipe Casado
Payer, Ángel Ramírez
Sierra, Magdalena
Marín, Francisca Ferrer
López, Raúl Pérez
Cirici, Blanca Xicoy
Steegmann, Juan Luis
Gómez Casares, María Teresa
Martínez-López, Joaquín
García-Gutiérrez, Valentín
Article History
Received: 2 December 2023
Accepted: 13 February 2024
First Online: 3 April 2024
Declarations
:
: The design, submission and monitoring of this study was performed in collaboration with the Contract Research Organization Fundación Teófilo Hernando, in accordance with their standard operating procedures, which comply with the ethical principles of Good Clinical Practice, and in accordance with the current Declaration of Helsinki (Fortaleza, Brazil, October 2013). The study was approved by the independent ethics committee of each participating center and by the Spanish Agency of Medicines and Health Products (AEMPS). All patients gave written informed consent.
: L. Pérez Lamas: Novartis; travel grants. Incyte; travel grants. B. Xicoy: Novartis, Incyte; travel grants, research funding, advisory board; BMS and Pfizer: travel grants, advisory board. R. Ayala: Advisory board member for BMS, Novartis and Incyte. Received speaker honoraria from Astellas, Novartis and BMS.F. Ferrer Marín: Advisory board member for BMS and Novartis. Received speaker honoraria from Novartis and BMS. Received grants from CTI and Incyte. V. Garcia-Gutierrez: Novartis; BMS; Incyte; Pfizer; travel grants, research funding, advisory board.